Not checkedNot checked for notices yet.
Angiotensin II in ECMO patients: a word of caution
Elio Antonucci, Fabio Silvio Taccone
Critical Care · 2019
doi:10.1186/s13054-019-2337-5 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
We read with interest the recent letter by Ostermann et al.[1] about the administration of angiotensin II (Ang II) in patients treated by extracorporeal membrane oxygenation (ECMO).The authors reported seven patients with severe cardiorespiratory or respiratory failure receiving Ang II infusion during ECMO in the setting of high catecholamine doses.After Ang II initiation, they found a significant increase in blood pressure and a quick reduction in the need of other vasopressors.Despite the novelty of these findings, a word of caution should also be considered.First, two patients were treated with veno-venous (VV) ECMO, that is often initiated in the case of severe acute respiratory distress syndrome (ARDS).Renin-angiotensin system (RAS) has been implicated in the pathogenesis of ARDS.In particular, Ang II is a pro-inflammatory molecule able to promote capillary leak and fibroproliferation.Also, Ang II may contribute to a significant constriction of the pulmonary circulation, potentially leading to reduced blood flow and to increased ventilation/perfusion mismatch [2].Opposite to the angiotensin-converting enzyme (ACE)/Ang II axis, RAS has a counter-regulatory axis, which is composed by angiotensin-(1-7) (Ang 1-7) and ACE2 [2].Since ACE2 can minimize the risk of acute lung injury, a
Abstract licence: CC BY-NC-ND
References8
- 3.
7 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.